Kelly Pendergrass

3.1k total citations · 1 hit paper
31 papers, 2.3k citations indexed

About

Kelly Pendergrass is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kelly Pendergrass has authored 31 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Kelly Pendergrass's work include Cancer Treatment and Pharmacology (10 papers), Nausea and vomiting management (7 papers) and Advanced Breast Cancer Therapies (7 papers). Kelly Pendergrass is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Nausea and vomiting management (7 papers) and Advanced Breast Cancer Therapies (7 papers). Kelly Pendergrass collaborates with scholars based in United States, Italy and Chile. Kelly Pendergrass's co-authors include Igor Bondarenko, Guy Jérusalem, Angelo Di Leo, Didier Verhoeven, Roberto Torres, Sally Garnett, Р. Ш. Хасанов, Luboš Petruželka, Miguel Martín and José Luiz Pedrini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Kelly Pendergrass

31 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

2010 453 citations Angelo Di Leo, Guy Jérusalem et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Kelly Pendergrass

Since Specialization

Citations

This map shows the geographic impact of Kelly Pendergrass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly Pendergrass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly Pendergrass more than expected).

Fields of papers citing papers by Kelly Pendergrass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelly Pendergrass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly Pendergrass. The network helps show where Kelly Pendergrass may publish in the future.

Co-authorship network of co-authors of Kelly Pendergrass

This figure shows the co-authorship network connecting the top 25 collaborators of Kelly Pendergrass. A scholar is included among the top collaborators of Kelly Pendergrass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelly Pendergrass. Kelly Pendergrass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study 2018 ·The Breast ·Angelo Di Leo, Guy Jérusalem, Roberto Torres, Didier Verhoeven, Kelly Pendergrass, Luca Malorni, (unknown), Miguel Martín	9
2	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia 2014 ·Blood ·James B. Bussel, David J. Kuter, Louis M. Aledort, Craig M. Kessler, Adam Cuker, Kelly Pendergrass, Shande Tang, Joe McIntosh	117
3	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology 2013 ·Breast Cancer Research and Treatment ·Sally Garnett, Miguel Martín, Guy Jérusalem, Luboš Petruželka, Roberto Torres, Igor Bondarenko, Р. Ш. Хасанов, Didier Verhoeven, José Luiz Pedrini, (unknown), Mikhail Lichinitser, Kelly Pendergrass, Justin P.O. Lindemann, Angelo Di Leo	17
4	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial 2013 ·JNCI Journal of the National Cancer Institute ·Angelo Di Leo, Guy Jérusalem, Luboš Petruželka, Roberto Torres, Igor Bondarenko, Р. Ш. Хасанов, Didier Verhoeven, José Luiz Pedrini, И А Смирнова, Mikhail Lichinitser, Kelly Pendergrass, Luca Malorni, Sally Garnett, Yuri Rukazenkov, Miguel Martín	232
5	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer breakdown → 2010 ·Journal of Clinical Oncology ·Angelo Di Leo, Guy Jérusalem, Luboš Petruželka, Roberto Torres, Igor Bondarenko, Р. Ш. Хасанов, Didier Verhoeven, José Luiz Pedrini, И А Смирнова, Mikhail Lichinitser, Kelly Pendergrass, Sally Garnett, Justin P.O. Lindemann, Francisco Sapunar, Miguel Martín	453
6	TPI 287, a third-generation taxane, is active and well tolerated as 2^nd line therapy after failure of docetaxel in hormone refractory prostate cancer (HRPC) 2008 ·Journal of Clinical Oncology ·Mitchell E. Gross, Kelly Pendergrass, S P Leitner, (unknown), (unknown), Simone Silberman	2
7	Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α 2008 ·Journal of Clinical Oncology ·Paul L. de Souza, Siniša Radulović, (unknown), Kelly Pendergrass, (unknown), (unknown), Anna Berkenblit, Alexandra Thiele, Mizue Krygowski, G. R. Hudes	7
8	A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS 2006 ·Annals of Oncology ·Tanja Trarbach, Pierre Major, Heinz‐Josef Lenz, DJ Kerr, Kelly Pendergrass, Jean‐Yves Douillard, (unknown), Amanda Littlewood‐Evans, Laurent Dembélé, Christian Jacques, Eric Van Cutsem	2
9	Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer 2006 ·Journal of Clinical Oncology ·Paul E. Goss, Igor Bondarenko, (unknown), Kelly Pendergrass, Wilson H. Miller, (unknown), W. Steve Lang, P. Langecker	5
10	Aprepitant: An oral NK1 antagonist for the prevention of nausea andvomiting induced by highly emetogenic chemotherapy 2004 ·Drugs of today ·Kelly Pendergrass, Richard Hargreaves, Kevin J. Petty, Alexandra D. Carides, Judith K. Evans, Kevin Horgan	24
11	Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist 1999 ·New England Journal of Medicine ·Rudolph M. Navari, (unknown), Richard J. Gralla, Mark G. Kris, Paul J. Hesketh, Ali Khojasteh, Hedy L. Kindler, Thomas Grote, Kelly Pendergrass, Steven M. Grunberg, Alexandra D. Carides, Barry J. Gertz	286
12	Options in the Treatment of Chemotherapy‐Induced Emesis 1998 ·Cancer Practice ·Kelly Pendergrass	19
13	Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. 1997 ·Journal of Clinical Oncology ·Sandra M. Swain, Fredrick S. Whaley, (unknown), Stuart P. Weisberg, Michael York, Darcy Spicer, Sarah E. Jones, Scott Wadler, Anjali Desai, Charles L. Vogel, James L. Speyer, A Mittelman, Salitha Reddy, Kelly Pendergrass, E Vélez-García, Michael S. Ewer, J. R. Bianchine, Richard A. Gams	466
14	Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. 1997 ·Journal of Clinical Oncology ·Mark G. Kris, Kelly Pendergrass, Rudolph M. Navari, Thomas Grote, Ashley M. Nelson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Steven B. Chernoff	19
15	High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin’s lymphoma: results of outpatient treatment in community cancer centers 1997 ·Bone Marrow Transplantation ·CH Weaver, Lee S. Schwartzberg, B Zhen, (unknown), Richard Leff, Kurt W. Tauer, Anne Rosenberg, Kelly Pendergrass, Paul Kaywin, John D. Hainsworth, FA Greco, West Wh, CD Buckner	25
16	Randomized phase III Study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer 1995 ·Cancer ·Dennie V. Jones, R Winn, (unknown), Lawrence B. Levy, Reginald P. Pugh, (unknown), Howard M. Gross, Kelly Pendergrass, B. Levin, James L. Abbruzzese	13
17	Efficacy of Oral Ondansetron, A Selective Antagonist of 5-HT3 Receptors, in the Treatment of Nausea and Vomiting Associated with Cyclophosphamide-Based Chemotherapies 1994 ·American Journal of Clinical Oncology ·Luigi X. Cubeddu, Kelly Pendergrass, Thomas Ryan, (unknown), Gary V. Burton, Michael W. Meshad, Daniel Galvin	30
18	Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. 1992 ·Journal of Clinical Oncology ·Thomas Beck, Paul J. Hesketh, Stefan Madajewicz, Rudolph M. Navari, Kelly Pendergrass, Eric P. Lester, Julie A. Kish, William K. Murphy, John D. Hainsworth, David R. Gandara	77
19	A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. 1991 ·Journal of Clinical Oncology ·John D. Hainsworth, W. Henwood Harvey, Kelly Pendergrass, Basil Kasimis, D J Oblon, (unknown), David R. Gandara, Paul J. Hesketh, Ali Khojasteh, Graydon Harker	121
20	Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. 1990 ·Journal of Clinical Oncology ·Thomas P. Miller, Steve Dahlberg, James K. Weick, Joe C. Files, Harmon J. Eyre, Kelly Pendergrass, Richard I. Fisher	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact